Pigmentary Disorders

Data from the TRuE-V mechanism of action study was presented in a poster at the 2024 RAVE Conference.

These findings may provide guidance for future international definitions of degrees of activity and repigmentation in vitiligo.

Clinicians, especially those who see patients with inflammatory and pigmentary disorders, should incorporate alcohol use disorder screening measures into all patient visits.

Topical Bacitracin, Neosporin, and Vaseline were applied to mice over a 6-week period.

In addition, authors of a research letter noted that patients with vitiligo demonstrated a comparable risk of myocardial infarction and cerebrovascular accident.

A new review highlighted JAK inhibitors' role in vitiligo treatment, emphasizing varying benefits, facial efficacy, and potential for sustained responses.

Study participants in the treatment group experienced an observable and significant decrease in melanin index scoring.

Researchers compared the potent depigmenting agent with modified Kligman's formula, considered the gold standard therapy for melasma.

Dive into a complex case report of a 29-year-old African American male patient with Fitzpatrick skin type V with a 6-month reported history of vitiligo on his lips.

The study suggests a relationship between an imbalance in the skin microbiota and LS-associated hypopigmentation.

Seemal Desai, MD, highlighted the challenges and opportunities to best serve patients seeking solutions for acne scars, melasma, vitiligo, and cosmetic concerns.

Investigators also developed a MELASQoL model using 4 predictors of quality of life impacts in patients with melasma.

Rebecca Vasquez, MD, presented a session on common, overlapping, and complex pigmented dermatoses.

UV exposure or trauma to the skin, such as blistering and ulceration, can lead to changes in skin pigmentation and appearance. 

Quality of life is impacted far beyond the physical challenges for those with oculocutaneous albinism.

Compared to patients without melasma, blue light irradiation caused minimal changes in patients with melasma.

Pediococcus acidilactici demonstrated significant clinical efficacy and potential in treating hyperpigmentation.

Nicole Gunasekera, MD, MBA, presented a session on disorders of pigmentation at the 2023 SDPA Annual Summer Dermatology Conference.

Cheryl Burgess, MD, FAAD, reviewed the symptoms and diagnoses of collected case studies of dermal filler AEs at SCALE 2023.

Ruxolitinib is the first and only approved treatment for repigmentation in the European Union.

Findings published in JDD suggest topical tranexamic acid can be used as first-line monotherapy.

The picosecond system has previously been approved for treating acne scarring, pigmented lesions, tattoo removal, and wrinkles.

At the 2022 Fall Clinical Dermatology Conference, 5 practitioners share their best tips for treating their patients

Pigmentary disorders of the skin can be the cause of significant psychological distress in affected patients.

At the SDPA 2022 Annual Summer Dermatology Conference, a session on both common and rare dermatological disorders.

Ruxolitinib cream 1.5% may soon be the first FDA-approved treatment for repigmentation of vitiligo. Experts share what dermatologists need to know regarding efficacy, safety, and cost of this topical drug.

The skincare manufacturer and distributer announced that it has received patents for hair growth and melasma.

In a presentation at the current AAD annual meeting, experts discussed differential diagnoses and clinical presentations in birthmarks and hamartomas.

Investigator Loren Krueger, MD, urges dermatologists to recognize and correct disparities in clinical decision-making, particularly regarding skin cancer.

Unsafe and toxic skin-whitening products continue to draw fire.